Opioid Induced Constipation News and Research

RSS
Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Progenics second-quarter total revenue decreases to $2.3 million

Progenics second-quarter total revenue decreases to $2.3 million

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Data from Phase II clinical trial of NKTR-118 presented

Data from Phase II clinical trial of NKTR-118 presented

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

AstraZeneca and Nektar Therapeutics enter worldwide license agreement for two drug development programmes

AstraZeneca and Nektar Therapeutics enter worldwide license agreement for two drug development programmes

Oral NKTR-118 has low risk for mediating significant drug-drug interactions

Oral NKTR-118 has low risk for mediating significant drug-drug interactions

Opioid antagonists show potential for problematic pain

Opioid antagonists show potential for problematic pain

Opioid antagonists help pain management

Opioid antagonists help pain management

FDA approves Relistor for opioid-induced constipation - helps reduce effects of drugs like morphine on bowel function

FDA approves Relistor for opioid-induced constipation - helps reduce effects of drugs like morphine on bowel function